Ripretinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), G-BA (Germany) and HAS (France), among others, recommended or restricted ripretinib, while DMC (Denmark) and NYE METODER (Norway) did not recommend it.
The record spans 4.8 years, opening at PBAC (Australia) in 2021 and running to 27 May 2026.
ZIN (Netherlands) changed its position: not recommended on 16 Jan 2025, recommended by 17 Oct 2025, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
The file is active: 11 of 16 records date from 2023 or later.
3 distinct indication wordings are recorded for ripretinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 16 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess ripretinib, in 2021; DMC (Denmark) did not open a file until 27 May 2026 — a wide spread of 4.8 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 6 years in total.
3 of the 12 agencies here assessed ripretinib more than once, CIPM (Spain) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
ripretinib has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for ripretinib reads 8 recommended, 6 not recommended, 1 appraised and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NICE (England) | 28 Apr 2026 | NICE TA1146 | published appraisal | source |
| NYE METODER (Norway) | 16 Nov 2025 | Behandling av voksne med avansert gastrointestinal stromal tumor (GIST) som har fått tidligere behandling med tre eller … | not introduced | source |
| ZIN (Netherlands) | 17 Oct 2025 | Advies - vergoed ripretinib (Qinlock®) voor de behandeling van zeldzame kanker in maag of darmen (herbeoordeling) | reimbursed (sluis) | source |
| SMC (Scotland) | 11 Aug 2025 | Treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatini… | accepted | source |
| CIPM (Spain) | 21 Feb 2024 | SECRETARIA DE ESTADO DE SANIDAD 19 MINISTERIO DE SANIDAD MINISTERIO DE SANIDAD Indicación terapéutica autorizada : Qinlo… | financed by the SNS · art. 92 a, c | source |
11 further decisions for ripretinib, across 9 agencies, are not shown here. They include the most recent record on file, 27 May 2026 from DMC (Denmark); its outcome is in the subscriber dataset. They link to 9 further source documents.
Related molecules
- pirtobrutinib — same ATC class L01 — Antineoplastics
- idecabtagene vicleucel — same ATC class L01 — Antineoplastics
- vutrisiran — also decided by DMC in 2026Q2
- ciltacabtagene autoleucel — also decided by DMC in 2026Q2
- tafasitamab — also decided by DMC in 2026Q2
- ravulizumab — also decided by DMC in 2026Q2
Coverage: 16 decisions for ripretinib from 12 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01 — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.